Rockwell Medical (NASDAQ:RMTI) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Rockwell Medical (NASDAQ:RMTI) from a hold rating to a sell rating in a research note issued to investors on Saturday.

RMTI has been the topic of a number of other research reports. HC Wainwright cut their price target on shares of Rockwell Medical from $3.00 to $2.50 and set a “buy” rating on the stock in a research report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Rockwell Medical in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $2.50.

Rockwell Medical Trading Up 0.7%

Rockwell Medical stock traded up $0.01 during mid-day trading on Friday, hitting $0.92. 355,735 shares of the stock were exchanged, compared to its average volume of 626,524. The stock has a market capitalization of $31.64 million, a price-to-earnings ratio of -15.32 and a beta of 1.68. Rockwell Medical has a 12 month low of $0.78 and a 12 month high of $2.59. The company has a quick ratio of 2.51, a current ratio of 2.89 and a debt-to-equity ratio of 0.30. The firm’s fifty day simple moving average is $1.23 and its two-hundred day simple moving average is $1.13.

Rockwell Medical (NASDAQ:RMTI) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Rockwell Medical had a negative return on equity of 6.79% and a negative net margin of 2.38%.The firm had revenue of $15.93 million during the quarter, compared to analyst estimates of $16.24 million. Rockwell Medical has set its FY 2025 guidance at EPS. Analysts forecast that Rockwell Medical will post 0.03 EPS for the current year.

Institutional Trading of Rockwell Medical

Several large investors have recently made changes to their positions in the company. GSA Capital Partners LLP raised its stake in shares of Rockwell Medical by 635.1% in the third quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock worth $197,000 after purchasing an additional 141,672 shares during the last quarter. Vanguard Group Inc. grew its holdings in Rockwell Medical by 12.3% during the third quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock worth $1,625,000 after buying an additional 148,737 shares in the last quarter. Finally, Panagora Asset Management Inc. purchased a new stake in Rockwell Medical in the 2nd quarter valued at $41,000. 23.31% of the stock is currently owned by institutional investors and hedge funds.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.